Compare ARCC & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARCC | HALO |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 12.0B |
| IPO Year | 2004 | 2001 |
| Metric | ARCC | HALO |
|---|---|---|
| Price | $18.57 | $110.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 9 |
| Target Price | $20.77 | ★ $101.75 |
| AVG Volume (30 Days) | ★ 4.4M | 2.4M |
| Earning Date | 10-27-2026 | 11-02-2026 |
| Dividend Yield | ★ 10.35% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.36 | ★ 3.11 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | $1.40 | $33.93 |
| Revenue Next Year | $3.06 | $10.74 |
| P/E Ratio | $51.47 | ★ $35.78 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.40 | $61.23 |
| 52 Week High | $21.14 | $116.85 |
| Indicator | ARCC | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 36.30 | 54.77 |
| Support Level | $18.38 | $105.27 |
| Resistance Level | $19.35 | $111.15 |
| Average True Range (ATR) | 0.27 | 3.05 |
| MACD | -0.06 | -0.55 |
| Stochastic Oscillator | 24.89 | 41.43 |
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.